Human-Computer Interaction Resource Network
| Trillin Heath - Manufacturer of LIFE-HGH | |
| LIFE-HGH - Triple potency recombinant (rDNA)oral HGH/Somatotropin products using HPUS approved ingredients. LIFE-HGH has everything the other HGH products have, plus a great deal more | |
| Keywords : HGH Spray, LIFE-HGH, HGH |
| Last Update : | 13/December/2011 |
| Google PR : | 2 |
| Internal links : | 4 |
| Archive : | Check how did the site look in the past? |
| Keyword | Occurrences | Percentage |
|---|---|---|
| life hgh | 7 | 9.15% |
| technology inc | 4 | 5.23% |
| health technology | 4 | 5.23% |
| trillin health | 4 | 5.23% |
| hgh beta | 2 | 2.61% |
| Keyword | Occurrences | Percentage |
|---|---|---|
| trillin health technology | 4 | 7.84% |
| health technology inc | 4 | 7.84% |
| products life hgh | 2 | 3.92% |
| hgh beta glucan | 2 | 3.92% |
| life hgh beta | 2 | 3.92% |
| Site IP address : | 216.170.92.60 |
| Server type : | Microsoft-IIS/5.0 |
| Powered by : | ASP.NET |
| DNS 1 : | ns.inlinenet.net |
| DNS 2 : | ns1.inlinenet.net |
| MX Domain 1 : | mail.trillin.net |
| Alexa rank : | no data |
| Description : | Trillin.net is located in the US. The site can be found in the “Homeopathic” category. The site has been online for at least ten years. |
| cell_renew | 28.51% |
| cell renew hgh | 23.40% |
| beta 1:3 straight | 19.85% |
| beta heath | 13.45% |
| beta glucan for japanese | 8.83% |
| trillin | 5.91% |
| psk mg | 0.05% |
| Quantcast rank : | 0 | Average US daily traffic : | 0 |
| Compete rank : | 0 |
| Average daily unique visitors : | 0 |
| MyWot rank : | 0 |
| Trustworthiness : | 70 |
| Vendor reliability : | 0 |
| Privacy : | 0 |
| Child safety : | 0 |
| youthfulagain.com | subtropin.com | problen.com | maximumresult.com | hghrevolution.com |
| hgh.ws | biomedcomm.com | 21stcenturyhgh.com | hgh-best-results.com | morehgh.com |
| trillian.im | trillian-deutsch.de | trillian-messenger.net | trilliumfoundation.org | trillian.de |
| trilliumhealthcentre.org | trillinet.de | trillinux.org | leo-willin.de |
|
|
|
|
|
|